Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct;53(5):703-8.
doi: 10.1007/s00592-016-0859-8. Epub 2016 Apr 22.

GCK-MODY in the US National Monogenic Diabetes Registry: frequently misdiagnosed and unnecessarily treated

David Carmody  1 , Rochelle N Naylor  2 , Charles D Bell  1 , Shivani Berry  1 , Jazzmyne T Montgomery  1 , Elizabeth C Tadie  1 , Jessica L Hwang  1 , Siri Atma W Greeley  3 , Louis H Philipson  3
Affiliations

GCK-MODY in the US National Monogenic Diabetes Registry: frequently misdiagnosed and unnecessarily treated

David Carmody et al. Acta Diabetol. 2016 Oct.

Abstract

Aims: GCK-MODY leads to mildly elevated blood glucose typically not requiring therapy. It has been described in all ethnicities, but mainly in Caucasian Europeans. Here we describe our US cohort of GCK-MODY.

Methods: We examined the rates of detection of heterozygous mutations in the GCK gene in individuals referred to the US Monogenic Diabetes Registry with a phenotype consistent with GCK-MODY. We also assessed referral patterns, treatment and demography, including ethnicity, of the cohort.

Results: Deleterious heterozygous GCK mutations were found in 54.7 % of Registry probands selected for GCK sequencing for this study. Forty-nine percent were previously unnecessarily treated with glucose-lowering agents, causing hypoglycemia and other adverse effects in some of the subjects. The proportion of probands found to have a GCK mutation through research-based testing was similar across each ethnic group. However, together African-American, Latino and Asian subjects represented only 20.5 % of screened probands and 17.2 % of those with GCK-MODY, despite higher overall diabetes prevalence in these groups.

Conclusions: Our data show that a high detection rate of GCK-MODY is possible based on clinical phenotype and that prior to genetic diagnosis, a large percentage are inappropriately treated with glucose-lowering therapies. We also find low minority representation in our Registry, which may be due to disparities in diagnostic diabetes genetic testing and is an area needing further investigation.

Keywords: GCK; Genetic testing; Glucokinase; MODY; Monogenic diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflicts of interest.

References

    1. Chakera AJ, Spyer G, Vincent N, et al. The 0.1% of the Population With Glucokinase Monogenic Diabetes Can be Recognized by Clinical Characteristics in Pregnancy: The Atlantic Diabetes in Pregnancy Cohort. Diabetes Care. 2014 doi: 10.2337/dc13-2248. - DOI - PubMed
    1. Sagen JV, Odili S, Bjørkhaug L, et al. From clinicogenetic studies of maturity-onset diabetes of the young to unraveling complex mechanisms of glucokinase regulation. 2006;55:1713–1722. doi: 10.2337/db05-1513. - DOI - PubMed
    1. Negahdar M, Aukrust I, Molnes J, et al. GCK-MODY diabetes as a protein misfolding disease: the mutation R275C promotes protein misfolding, self-association and cellular degradation. 2014;382:55–65. doi: 10.1016/j.mce.2013.08.020. - DOI - PubMed
    1. Matschinsky FM. Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics. 2002;51(3):S394–404. - PubMed
    1. Davis EA, Cuesta-Munoz A, Raoul M, et al. Mutants of glucokinase cause hypoglycaemia- and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis. 1999;42:1175–1186. doi: 10.1007/s001250051289. - DOI - PubMed